Cell-of-origin chromatin organization shapes the mutational landscape of cancer
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
An analysis of cell-type-specific epigenomic features reveals a relationship between epigenomic and mutational profiles; chromatin characteristics can explain a large proportion of mutational variance in cancer genomes and the mutational distribution can identify the probable cell type from which a given cancer originated from. Genomic studies have shown that different cancer types vary substantially in the local density and types of somatic mutations. This has been explained not only by differences in DNA sequence but also by other features including epigenetic organization. Shamil Sunyaev and colleague now compare mutation densities to detailed epigenetic profiles of different cell types and tissues. They demonstrate that epigenomic features of a given cell type or tissue in which a cancer arises are much stronger determinants of mutational profiles than other properties. Conversely, the findings make it possible to deduce information on the possible tissue-of-origin of a tumour based on its mutational landscape. Cancer is a disease potentiated by mutations in somatic cells. Cancer mutations are not distributed uniformly along the human genome. Instead, different human genomic regions vary by up to fivefold in the local density of cancer somatic mutations1, posing a fundamental problem for statistical methods used in cancer genomics. Epigenomic organization has been proposed as a major determinant of the cancer mutational landscape1,2,3,4,5. However, both somatic mutagenesis and epigenomic features are highly cell-type-specific6,7. We investigated the distribution of mutations in multiple independent samples of diverse cancer types and compared them to cell-type-specific epigenomic features. Here we show that chromatin accessibility and modification, together with replication timing, explain up to 86% of the variance in mutation rates along cancer genomes. The best predictors of local somatic mutation density are epigenomic features derived from the most likely cell type of origin of the corresponding malignancy. Moreover, we find that cell-of-origin chromatin features are much stronger determinants of cancer mutation profiles than chromatin features of matched cancer cell lines. Furthermore, we show that the cell type of origin of a cancer can be accurately determined based on the distribution of mutations along its genome. Thus, the DNA sequence of a cancer genome encompasses a wealth of information about the identity and epigenomic features of its cell of origin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutation rates vary in different parts of the genome, at different stages of the life cycle and in diseases such as cancer, where they depend on the cell of origin, environmental exposure and cancer type [60][61][62] .”
From Advances in epigenetics link genetics to the environment and disease (2019) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Integrative analysis of 111 reference human epigenomes
Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015) · Nature · doi:10.1038/nature14248 · Cited by 6,368
Self-citationMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Self-citationComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Self-citationPermutation importance: a corrected feature importance measure
Altmann, A., Toloşi, L., Sander, O., & Lengauer, T. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq134 · Cited by 2,843
The accessible chromatin landscape of the human genome
Thurman, R. E., Rynes, E., Humbert, R., Vierstra, J., Maurano, M. T., Haugen, E., Sheffield, N. C., Stergachis, A. B., Wang, H., Vernot, B., et al. (2012) · Nature · doi:10.1038/nature11232 · Cited by 2,679
Self-citation
Cited by
Items 301–400 of 548
Recent insights into mechanisms preventing ectopic centromere formation
Dong, Q., Yang, J., Gao, J., & Li, F. (2021) · Open Biology · doi:10.1098/rsob.210189 · Cited by 12
Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas
Machino, H., Dozen, A., Konaka, M., Komatsu, M., Nakamura, K., Ikawa, N., Shozu, K., Asada, K., Kaneko, S., Yoshida, H., et al. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01090-1 · Cited by 12
“…[12] を評価できる ATAC-seq [12] 解析では、 RNA-seq と比較して、腫瘍形成能を獲得した細胞( HTKA 、 HTKM ) のプロファイルをより明瞭に抽出することができました(図 1b )。これはエピゲ ノム解析が、正確な細胞情報を取得するために重要であることを示唆していま す。 ATAC-seq データを基に、転写因子の DNA 結合モチーフ [13] の変動を網羅的に 評価したところ、腫瘍形成能を獲得する過程で AP-1 ファミリーの転写因子が活 ―――――――――――――――――――――――――――――――――――――― 町野英徳”
Linking the organization of DNA replication with genome maintenance
Singh, B., & Wu, P.-Y. J. (2019) · Current Genetics · doi:10.1007/s00294-018-0923-8 · Cited by 12
Tissue-specific impact of stem-loops and quadruplexes on cancer breakpoints formation
Cheloshkina, K., & Poptsova, M. S. (2019) · BMC Cancer · doi:10.1186/s12885-019-5653-x · Cited by 13
Targeting transcriptional regulators for treatment of anaplastic thyroid cancer
Lee, W. K., & Cheng, S.-Y. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.58 · Cited by 12
“Interestingly, the chromatin features of cell-of-origin are known to be strong predictors for cancer mutation profiles[73], suggesting chromatin alterations as critical drivers for cancer development.”
BackgroundPathScore: a web tool for identifying altered pathways in cancer data
Gaffney, S. G., & Townsend, J. P. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw512 · Cited by 11
Chromatin marks shape mutation landscape at early stage of cancer progression
Ha, K., Kim, H., & Lee, H.-J. (2017) · npj Genomic Medicine · doi:10.1038/s41525-017-0010-y · Cited by 11
“Whole-genome analyses of distinct cancer types depict cell-oforigin chromatin marks as the strongest feature explaining the cancer mutation landscape, with a number of proposed mechanisms.(10) Based on the IGHV mutation status-based clustering of MBL and CLL tissues in PCOA, we hypothesized that differential IGHV muta…”
BackgroundPrinciples and methods of integrative chromatin analysis in primary tissues and tumors
Cejas, P., & Long, H. W. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.188333 · Cited by 13
DNA polymerase κ participates in early S-phase DNA replication in human cells
Tang, F., Wang, Y., Zhao, T. S., Yuan, J. J., Kellum, A. H., & Wang, Y. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2405473121 · Cited by 12
“Genomic regions replicated early in the S phase tend to be enriched with clusters of DNase I - hypersensitive sites, exhibit high transcriptional activity, and accrue less mutations than those replicated late in the S phase (1, 2).”
InfluentialOncogenic competence: balancing mutations, cellular state, and microenvironment
Pavinato, L., & Baggiolini, A. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.01.002 · Cited by 12
Shetty, A. H., Seo, J.-H., Bell, C. A., O’Connor, E. P., Pomerantz, M. M., Freedman, M. L., & Gusev, A. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.09.008 · Cited by 10
The impact of chromatin on double-strand break repair: Imaging tools and discoveries
van Bueren, M. A. E., & Janssen, A. (2023) · DNA repair · doi:10.1016/j.dnarep.2023.103592 · Cited by 14
Predicting the recurrence of noncoding regulatory mutations in cancer
Yang, W., Bang, H., Jang, K., Sung, M. K., & Choi, J. K. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1385-y · Cited by 10
“[6] found that cell-oforigin chromatin features are a strong determinant of the distribution of cancer mutations.”
BackgroundThe evolution of leukaemia from pre‐leukaemic and leukaemic stem cells
Shlush, L. I., & Feldman, T. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13236 · Cited by 11
Zhao, Z., Zhang, X., Li, Z., Gao, Y., Guan, X., Jiang, Z., Liu, Z., Yang, M., Chen, H., Ma, X., et al. (2021) · PubMed Central · Cited by 10
Epigenomic Consequences of Coding and Noncoding Driver Mutations
Yao, X., Xing, M., Ooi, W. F., Tan, P. B. O., & Teh, B. T. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.09.002 · Cited by 11
“Importantly, genome-wide analysis across different cell types suggests that epigenetic features may explain the cell-type-specific manner in which some mutations occur [147], even though the precise mechanism responsible for acquiring specific mutations in a particular lineage remains to be investigated.”
Depletion of somatic mutations in splicing-associated sequences in cancer genomes
Hurst, L. D., & Batada, N. N. (2017) · Genome biology · doi:10.1186/s13059-017-1337-5 · Cited by 10
Dysregulation of the cohesin subunit RAD21 by Hepatitis C virus mediates host–virus interactions
Perez, S., Gevor, M., Davidovich, A., Kaspi, A., Yamin, K., Domovich, T., Meirson, T., Matityahu, A., Brody, Y., Stemmer, S. M., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz052 · Cited by 10
“The histone modification histone H3 acetylated on lysine 9 (H3K9Ac), that is an epigenetic marker for transcriptional activation, was previously associated with liver-specific epigenetics (46,47).”
BackgroundA site specific model and analysis of the neutral somatic mutation rate in whole-genome cancer data
Bertl, J., Guo, Q., Juul, M., Besenbacher, S., Nielsen, M. M., Hornshøj, H., Pedersen, J. S., & Hobolth, A. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2141-2 · Cited by 10
“This is of particular interest for epigentic measurements like histone modifications, where the tissue of origin has been shown to be informative [4].”
BackgroundMethodInfluentialThe cause of cancer mutations: Improvable bad life or inevitable stochastic replication errors?
Алексеенко, И. В., Kuzmich, A. I., Pleshkan, V. V., Tyulkina, D. V., Zinovyeva, M. V., Костина, М. Б., & Sverdlov, E. D. (2016) · Molecular Biology · doi:10.1134/s0026893316060030 · Cited by 9
Abdollahi, S., Dehghanian, S. Z., Hung, L., Yang, S.-J., Chen, D.-P., Medeiros, L. J., Chiang, J.-H., & Chang, K. (2021) · Biomarker Research · doi:10.1186/s40364-021-00330-8 · Cited by 9
Cell-type specificity of the human mutation landscape with respect to DNA replication dynamics
Caballero, M., Boos, D., & Koren, A. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100315 · Cited by 11
Self-citationCramer, D., Serrano, L., & Schaefer, M. H. (2016) · eLife · doi:10.7554/elife.16519 · Cited by 12
“This prevented us from correlating CNA numbers from different cancer types with epigenetic marks in the respective tissue-of-origin using windows with a sufficient genomic resolution, as has been done for SNVs (Polak et al., 2015).”
BackgroundMethodResultInfluentialLu, J., Li, H., Eastman, A. E., Sasaki, T., Gilbert, D. M., & Lerou, P. H. (2016) · Stem Cells and Development · doi:10.1089/scd.2015.0393 · Cited by 11
“In addition, replication timing clearly influences genomic mutation rates [15,16].”
Chen, H., Kichaev, G., Bien, S. A., MacDonald, J. W., Wang, L., Bammler, T. K., Auer, P. L., Paşaniuc, B., & Lindström, S. (2019) · Human Genetics · doi:10.1007/s00439-019-02041-5 · Cited by 9
Translational Opportunities for Microfluidic Technologies to Enable Precision Epigenomics
Xu, Y. F., Doonan, S. R., Ördög, T., & Bailey, R. C. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c01288 · Cited by 10
Epigenetic reader chromodomain as a potential therapeutic target
Sharma, S., Hampton, J. T., Kutateladze, T. G., & Liu, W. R. (2025) · RSC Chemical Biology · doi:10.1039/d4cb00324a · Cited by 8
Wang, H., Du, S., Ji, S., Miao, G., Yu, J., Zhou, M., Zhang, Y., Li, X., Ma, W., Li, A., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217933 · Cited by 8
In silico generation of synthetic cancer genomes using generative AI
Díaz‐Navarro, A., Zhang, X., Jiao, W., Wang, B., & Stein, L. D. (2025) · Cell Genomics · doi:10.1016/j.xgen.2025.100969 · Cited by 13
Zhang, X., Zhou, Y., Shi, Z., Liu, Z., Chen, H., Wang, X., Cheng, Y., Xi, L., Li, X., Zhang, C., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.953 · Cited by 8
Leveraging Gene Redundancy to Find New Histone Drivers in Cancer
Ostroverkhova, D. S., Espiritu, D., Aristizabal, M. J., & Panchenko, A. R. (2023) · Cancers · doi:10.3390/cancers15133437 · Cited by 8
“Collectively, these factors have been shown to explain up to 86% of the variance in cancer mutation rates [41].”
BackgroundSequence dependencies and mutation rates of localized mutational processes in cancer
Poulsgaard, G. A., Sørensen, S. G., Juul, R. I., Nielsen, M. M., & Pedersen, J. S. (2023) · Genome Medicine · doi:10.1186/s13073-023-01217-z · Cited by 14
Role of Chromatin Modifying Complexes and Therapeutic Opportunities in Bladder Cancer
Meghani, K. A., Cooley, L. F., Piunti, A., & Meeks, J. J. (2022) · Bladder Cancer · doi:10.3233/blc-211609 · Cited by 9
“More importantly, in 74 a manner unique to cell-of-origin, epigenetic sta75 tus impacts chromatin packaging which regulates the 76 genomic mutational landscape [29, 30].”
BackgroundShort-Circuiting Gene Regulatory Networks: Origins of B Cell Lymphoma
Koues, O. I., Oltz, E. M., & Payton, J. E. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.09.006 · Cited by 12
Androgen receptor binding sites are highly mutated in prostate cancer
Morova, T., Gönen, M., Dalal, K., Gürsoy, A., Keskin, O., & Lack, N. A. (2019) · Oncology Abstracts · doi:10.1530/oncolabs.1.p030 · Cited by 8
Cao, H., Jin, M., Gao, M., Zhou, H., Tao, Y. J., & Skolnick, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-63061-0 · Cited by 11
Thomas, P. B., Jeffery, P. L., Gahete, M. D., Whiteside, E., Walpole, C., Maugham, M., Jovanovic, L., Gunter, J. H., Williams, E. D., Nelson, C. C., et al. (2021) · PeerJ · doi:10.7717/peerj.10280 · Cited by 10
G-Quadruplex Matters in Tissue-Specific Tumorigenesis by BRCA1 Deficiency
Kim, S., & Hwang, S. (2022) · Genes · doi:10.3390/genes13030391 · Cited by 9
“It is generally accepted that chromatin organization and replication timing shape the mutational landscape of cancer together [61,73,74], and are in fact associated with each other [75].”
BackgroundRecurring urothelial carcinomas show genomic rearrangements incompatible with a direct relationship
Marzouka, N., Lindgren, D., Eriksson, P., Sjödahl, G., Bernardo, C., Liedberg, F., Axelson, H., & Höglund, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-75854-4 · Cited by 8
Exploring epigenetics with chemical tools
Zhang, Y., & Kutateladze, T. G. (2020) · Nature Chemistry · doi:10.1038/s41557-020-0471-y · Cited by 8
Ganz, J., Luquette, L. J., Bizzotto, S., Bohrson, C. L., Jin, H., Miller, M. B., Zhou, Z., Galor, A., Park, P. J., & Walsh, C. A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.14.523958 · Cited by 9
A comprehensive view of somatic mosaicism by single-cell DNA analysisPreprint
Luquette, L. J., Coorens, T. H. H., Natu, A., Šuvakov, M., Caplin, A. H., Jun, M. S., Mo, A., Pelt, J., Anderson, L., Berselli, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.31.685648 · Cited by 13
Non-B DNA structures and their contributions to genetic diversity, aging, and disease
Bochalis, E., Dereki, I., Wang, G., Sgourou, A., Vásquez, K. M., & Georgakopoulos‐Soares, I. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag084 · Cited by 16
Network perturbation by recurrent regulatory variants in cancer
Jang, K., Kim, K., Cho, A., Lee, I., & Choi, J. K. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005449 · Cited by 14
Applications of ENCODE data to systematic analyses via data integration
Zhao, Y., Schaafsma, E., & Cheng, C. (2018) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2018.08.010 · Cited by 9
“This association between chromatin features and mutation density is highly cell-type specific and mutations tend to be enriched in heterochromatin [52].”
BackgroundYang, S., Ha, K., Song, W., Fujita, M., Kübler, K., Polak, P. P., Rivas, C. G. D. A., Pessina, P., de Aja, J. S., Rowbotham, S., et al. (2022) · Life · doi:10.3390/life13010071 · Cited by 8
“Although mechanisms on how these aberrations arise have not been fully defined, a number of statistical and machine-learning approaches have shown that the somatic point mutation landscapes of multiple cancer types and precancerous lesions correlated with the chromatin mark landscape [23,24].”
BackgroundMethodResultInfluentialSelf-citationTissue-Predisposition to Cancer Driver Mutations
Peters, L., Venkatachalam, A., & Ben‐Neriah, Y. (2024) · Cells · doi:10.3390/cells13020106 · Cited by 10
Panzeri, I., Fagnocchi, L., Apostle, S., Tompkins, M., Wolfrum, E., Madaj, Z., Hostetter, G. H., Liu, Y., Schaefer, K., Yang, C.-H., et al. (2025) · Nature Cancer · doi:10.1038/s43018-024-00900-3 · Cited by 9
Retinoblastoma protein regulates carcinogen susceptibility at heterochromatic cancer driver loci
Wong, K. M., King, D. A., Schwartz, E. K., Herrera, R. E., & Morrison, A. J. (2022) · Life Science Alliance · doi:10.26508/lsa.202101134 · Cited by 8
“…repressive heterochromatic regions accumulate more mutations than transcriptionally active euchromatin (Schuster-B¨ockler & Lehner, 2012; Polak et al, 2015), which is contributed by lack of transcription-coupled repair in non-genic regions and inef fi cient global genomic repair in…”
Kikutake, C., & Suyama, M. (2022) · Cancer Medicine · doi:10.1002/cam4.4749 · Cited by 10
“To investigate the co- occurrence of mutations and genome amplification in each open chromatin region, samples were divided into four groups: (1) regions with both mutations and genome amplification, (2) regions with only mutations, (3) regions with only genome amplification, and (4) regions with neither mutation nor…”
BackgroundMethodCirculating cell-free DNA sequencing for early detection of lung cancer
Xue, R., Yang, L., Yang, M., Xue, F., Li, L., Liu, M., Ren, Y., Qi, Y., & Zhao, J. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2224504 · Cited by 7
“Alterations in fragmentation patterns reflect changes in the chromatin structure before cfDNA release and other genomic and epigenomic alterations during tumorigenesis [59,60].”
BackgroundBarozzi, I., Slaven, N., Canale, E., Lopes, R., Barbosa, I. A. M., Bleu, M., Ivanoiu, D., Pacini, C., Mensa’, E., Chambers, A., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1157 · Cited by 9
“CRE activity is largely tissue specific and contributes to many aspects of cancer etiology (4–6).”
Forootan, S. S., Butler, J. M., Gardener, D., BAIRD, A. E., Dodson, A. R., Darby, A. C., Kenny, J. G., Hall, N., Cossins, A. R., Foster, C. S., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3222 · Cited by 8
On what to permute in test-based approaches for variable importance measures in Random Forests
Nembrini, S. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty1025 · Cited by 9
Heredia‐Genestar, J. M., Marquès‐Bonet, T., Juan, D., & Navarro, A. (2020) · Nature Communications · doi:10.1038/s41467-020-16296-4 · Cited by 7
Studying the Hepatitis C Virus-Induced Epigenetic Signature After Cure with Direct-Acting Antivirals
Perez, S., & Gal-Tanamy, M. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8976-8_13 · Cited by 10
Tumour promotion through the lens of evolution
López-Bigas, N., Kandyba, E. E., González-Pérez, A., Brennan, P., & Balmain, A. (2026) · Nature · doi:10.1038/s41586-026-10386-x · Cited by 9
Tomková, M., Tomek, J., Chow, J. C., McPherson, J. D., Segal, D. J., & Hormozdiari, F. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac1251 · Cited by 10
A new era of mutation rate analyses: Concepts and methods
Wu, K., 浙江大学医学院生命演化研究中心和第四附属医院, 浙. 杭. 3., Qin, D., Qian, Y., & Liu, H. (2024) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2024.058 · Cited by 8
Developmental Insights into Lung Cancer
Desai, T. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070820-032858 · Cited by 6
Fundamentally low reproducibility in molecular genetic cancer research
Алексеенко, И. В., Pleshkan, V. V., MONASTYRSKAYA, G. S., Kuzmich, A. I., Snezhkov, E. V., Didych, D. A., & Sverdlov, E. D. (2016) · Russian Journal of Genetics · doi:10.1134/s1022795416070036 · Cited by 6
ScalpelSig Designs Targeted Genomic Panels from Data to Detect Activity of Mutational Signatures
Franzese, N., Fan, J., Sharan, R., & Leiserson, M. D. M. (2022) · Journal of Computational Biology · doi:10.1089/cmb.2021.0453 · Cited by 6
“For intuition, we refer to previous work which shows a strong relationship between cancer type and regional mutation density (Jiao et al., 2020), as well as other regionally varying chromatin features (Polak et al., 2015).”
Ocsenas, O., & Reimand, J. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010393 · Cited by 8
“Regional mutation burden is associated with epigenetic information of related normal cells, suggesting that cells of cancer origin contribute to somatic variation [26] and allowing classification of cancers of unknown origin [27].”
BackgroundUusküla-Reimand, L., & Wilson, M. D. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.003 · Cited by 6
Taipale, J. (2018) · Science · doi:10.1126/science.aav3494 · Cited by 6
Passenger mutations link cellular origin and transcriptional identity in human lung adenocarcinomas
Panja, S., Mantri, P., Johnson, K. E., Andrade-Martínez, J. S., Yang, S., Deshpande, A. S., Tian, H., Beg, S., Ohara, K., Leal, A., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02418-5 · Cited by 5
“Previous studies have exploited this principle to derive classifiers that predict tissue-of-origin from the genome-wide distribution of passenger mutations 18,21–23 .”
Self-citationHotspot propensity across mutational processes
Arnedo-Pac, C., Muiños, F., González-Pérez, A., & López-Bigas, N. (2023) · Molecular Systems Biology · doi:10.1038/s44320-023-00001-w · Cited by 9
Shahid, A. M., Vainchenker, W., & Constantinescu, S. N. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70700 · Cited by 7
“Significant findings have shown that variations in epigenetic control, specific to cell type and stage of differentiation, dictate the timing and location of cellular transformation [15–17].”
NIMBus: a negative binomial regression based Integrative Method for mutation Burden Analysis
Zhang, J., Liu, J. J., McGillivray, P. D., Yi, C., Lochovsky, L., Lee, D., & Gerstein, M. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-03758-1 · Cited by 5
Martinez‐Fundichely, A., Dixon, A., & Khurana, E. (2022) · Nature Communications · doi:10.1038/s41467-022-32945-2 · Cited by 5
“While numerous computational methods have been developed to model the background distribution of single-nucleotide variants (SNVs)andidentifydriversinatissue-speci fi cmanner,similarmethods for SVs are lacking 5,10 – 13 .”
MethodALTRE: workflow for defining ALTered regulatory elements using chromatin accessibility data
Baskin, E., Farouni, R., & Mathé, E. A. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx386 · Cited by 5
Can the epigenome contribute to risk stratification for cancer onset?
Lelièvre, S. A. (2021) · NAR Cancer · doi:10.1093/narcan/zcab043 · Cited by 5
Intrinsic Molecular Processes: Impact on Mutagenesis
Lim, B., Mun, J., & Kim, S. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.03.009 · Cited by 5
“used cell-of-origin epigenomic features generated in the Roadmap Epigenomics Project[418_TD$DIFF] [25].”
BackgroundMethodNiculescu, V. F. (2018) · Journal of Cancer Genetics and Biomarkers · doi:10.14302/issn.2572-3030.jcgb-18-2183 · Cited by 6
“[97] consider cancer as a “regulatory and epigenetic program that is superimposed on a cell and the result is the development of genetic and genomic instability””
BackgroundHulke, M. L., Siefert, J. C., Sansam, C. L., & Koren, A. (2019) · Genome Biology and Evolution · doi:10.1093/gbe/evz098 · Cited by 6
Self-citationDark-matter matters: Discriminating subtle blood cancers using the darkest DNA
Parida, L., Haferlach, C., Rhrissorrakrai, K., Utro, F., Levovitz, C., Kern, W., Nadarajah, N., Twardziok, S. O., Hütter, S., Meggendorfer, M., et al. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007332 · Cited by 5
A comprehensive resource for retrieving, visualizing, and integrating functional genomics data
Blum, M., Cholley, P., Malysheva, V., Nicaise, S., Moehlin, J., Gronemeyer, H., & Mendoza-Parra, M. A. (2019) · Life Science Alliance · doi:10.26508/lsa.201900546 · Cited by 6
“ATAC-seq chromatin accessibility landscapes are well established to reveal cell identity and search the cell-of-origin in the case of cancer (Polak et al, 2015; Corces et al, 2016).”
BackgroundRovirosa, L., Ramos-Morales, A., & Javierre, B. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.592087 · Cited by 5
“Mutations preferentially cluster at regulatory elements characteristic to the cell-type from which the tumor originates (75).”
BackgroundSavary, C., Picard, C., Corradini, N., & Castets, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116310 · Cited by 6
Zhang, L., Deng, T., Liufu, Z., Liu, X., Chen, B., Hu, Z., Liu, C., Tracy, M. E., Lu, X., Wen, H., et al. (2024) · eLife · doi:10.7554/elife.99340 · Cited by 5
Hayashi, A., Ho, Y.-J., Makohon-Moore, A. P., Zucker, A., Hong, J., Umeda, S., Karnoub, E.-R. R., Huang, J., Baez, P., Kappagantula, R. L., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0167 · Cited by 5
“59, 60) and differences in DNA repair efficiency among different regions of the genome (59, 61).”
Reconstructing the lifelong history of cells and tissues via somatic mutation analysis
Faienza, S., Margaria, J. P., & Franco, I. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05946-9 · Cited by 4
“But at the same time, chromatin organization affects DNA accessibility to mutagens and DNA repair, thus influencing mutation accu - mulation [ 86 , 87].”
Zhang, T., Wang, Z., Zhang, B., & Tang, X. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108315 · Cited by 6
Systems Biology Approaches for Understanding Genome Architecture
Sewitz, S. A., & Lipkow, K. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3631-1_9 · Cited by 4
Our Genome's “Dark Matter” Is the Next Frontier in Molecular Diagnostics
Nerenz, R. D., & Lefferts, J. A. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.268607 · Cited by 4
Pratt, H., & Weng, Z. (2018) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2018.09.002 · Cited by 5
SMuRF: a novel tool to identify regulatory elements enriched for somatic point mutations
Guilhamon, P., & Lupien, M. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2501-y · Cited by 4
CT-FOCS: a novel method for inferring cell type-specific enhancer–promoter maps
Hait, T. A., Elkon, R., & Shamir, R. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac048 · Cited by 6
ALTRE: workflow for defining ALTered Regulatory Elements using chromatin accessibility data
Baskin, E., Farouni, R., & Mathé, E. A. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw688 · Cited by 4
MoCoLo: a testing framework for motif co-localization
Xu, Q., del Mundo, I. M. A., Zewail‐Foote, M., Luke, B. T., Vásquez, K. M., & Kowalski, J. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae019 · Cited by 4
Lau, K. W., Seng, C., Lim, T. K. H., & Tan, D. S. W. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.08.42 · Cited by 4
“Chromatin structure has been shown to influence the mutation rates in cancer cells (14-16).”
BackgroundCoupling Large-Scale Omics Data for Deciphering Systems Complexity
Nehme, A., Awada, Z., Kobeissy, F. H., Mazurier, F., & Zibara, K. (2018) · RNA technologies · doi:10.1007/978-3-319-92967-5_8 · Cited by 4
Smith, T., Carr, A. M., & Eyre‐Walker, A. (2016) · PeerJ · doi:10.7717/peerj.2391 · Cited by 4
Non-canonical secondary structures arising from non-B-DNA motifs are determinants of mutagenesisPreprint
Georgakopoulos‐Soares, I., Morganella, S., Jain, N., Hemberg, M., & Nik‐Zainal, S. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/146621 · Cited by 4
Jiang, L., Zheng, J., Kwan, J. S. H., Dai, S., Li, C., Li, M. J., Yu, B., To, K. F., Sham, P. C., Zhu, Y., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/437061 · Cited by 4
Mazrooei, P., Kron, K. J., Zhu, Y., Mehdi, T., Zhou, S., Ahmed, M., Severson, T., Guilhamon, P., Armstrong, N. S., Huang, V., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3245213 · Cited by 5
The epipliancy journey: Tumor initiation at the mercy of identity crisis and epigenetic drift
Benhassoun, R., Morel, A., Jacquot, V., Puisieux, A., & Ouzounova, M. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189307 · Cited by 4
Analysis of Shared Variants between Cancer Biospecimens
Foote, M. B., White, J. R., Chatila, W. K., Argilés, G., Lu, S., Rousseau, B., Artz, O., Johannet, P. M., Walch, H. S., Patel, M., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1583 · Cited by 4
Villanueva, M. T. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3934 · Cited by 3
The delicate relationship between DNA replication timing and gene expression
Greenberg, A., Blumenfeld, B., & Simon, I. (2020) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2020.06.001 · Cited by 3
Metadata
- Authors
- Polak, P., Karlić, R., Koren, A., Thurman, R., Sandstrom, R., Lawrence, M. S., Reynolds, A., Rynes, E., Vlahoviček, K., Stamatoyannopoulos, J. A., & Sunyaev, S. R.
- Affiliations
- Broad Institute (US)
- University of Zagreb (HR)
- University of Washington (US)
- Corresponding author
- Stamatoyannopoulos, John A.
- Sunyaev, Shamil R.
- ORCID
- Venue
- Nature
- Published
- 2015-02-18
- Volume
- 518
- Issue
- 7539
- Pages
- 360-364
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4405175
- OpenAlex
- W2086239585
- Cited by
- 557
- References
- 29
- Citations by year
- 2026: 22 · 2025: 31 · 2024: 41 · 2023: 41 · 2022: 46 · 2021: 56 · 2020: 55 · 2019: 62 · 2018: 46 · 2017: 60 · 2016: 65 · 2015: 29
- FWCI
- 22.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (HL53750)
- National Heart, Lung, and Blood Institute (P01HL053750, P01 HL53750)
- National Institute of Mental Health (R01MH101244)
- National Human Genome Research Institute (U54HG007010)
- National Cancer Institute (U54CA143874)
- National Institute of Environmental Health Sciences (U01ES017156)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- cell of origin, chromatin accessibility, chromatin modification, DNA replication timing, somatic mutations, mutation density, tissue of origin prediction, cancer cell lines
- MeSH terms
- Chromatin, Humans, Melanocytes, Melanoma, Mutation, Neoplasms, Organ Specificity, Genome, Human, DNA Replication Timing, Epigenesis, Genetic, Cell Line, Tumor, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.